B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/6/2019 |
| Start Date: | December 1999 |
| End Date: | January 2021 |
| Contact: | Yasmine Kieso, MSCR |
| Email: | ykieso@nshs.edu |
B-CLL Subgroups: Maturation Stage and Gene Expression
B type chronic lymphocytic leukemia (B-CLL) is the most prevalent leukemia in the western
world. It is a disease that occurs primarily in aging individuals and occurs more frequently
in males than females. Although B-CLL was considered a homogeneous condition, recent studies
by our laboratory and others suggest that B-CLL cases can be divided into two subgroups.
These sub-groups can be identified by either the presence or the absence of mutations in
antibody genes and/or by the percentage of B-CLL cells expressing a particular protein called
CD38. These two sub-groups (unmutated antibody genes high percent CD38 and mutated antibody
genes low percentage CD38) follow strikingly clinically different courses. For example, the
unmutated/CD38+ group experiences a much more aggressive disease and these patients almost
invariably die much sooner than the cases in the other group. In addition, the patients in
the mutated CD38+ group require much more chemotherapy than mutatedlCD38-. Finally,
surprisingly there is a much higher representation of males in the poor outcome unmutated
CD38 group than in the better outcome group. The reasons for these differences in clinical
outcome and gender bias are unknown.
world. It is a disease that occurs primarily in aging individuals and occurs more frequently
in males than females. Although B-CLL was considered a homogeneous condition, recent studies
by our laboratory and others suggest that B-CLL cases can be divided into two subgroups.
These sub-groups can be identified by either the presence or the absence of mutations in
antibody genes and/or by the percentage of B-CLL cells expressing a particular protein called
CD38. These two sub-groups (unmutated antibody genes high percent CD38 and mutated antibody
genes low percentage CD38) follow strikingly clinically different courses. For example, the
unmutated/CD38+ group experiences a much more aggressive disease and these patients almost
invariably die much sooner than the cases in the other group. In addition, the patients in
the mutated CD38+ group require much more chemotherapy than mutatedlCD38-. Finally,
surprisingly there is a much higher representation of males in the poor outcome unmutated
CD38 group than in the better outcome group. The reasons for these differences in clinical
outcome and gender bias are unknown.
Inclusion Criteria:
- 18 years of age,
- Patients must be able to contribute the required amount of blood without compromising
their well being,
- Participants must be willing to be contacted again in the future for additional blood
drawing.
Exclusion Criteria:
- Patients who are known to be anemic, with a hemoglobin < 8,
- Patients who are known to be infected with HIV.
We found this trial at
1
site
Manhasset, New York 11030
Principal Investigator: Nicholas Chiorazzi, M.D
Click here to add this to my saved trials
